drugset / Trial / NCT05845489

Summary

The investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy. The trial will test the hypothesis that clopidogrel is beneficial in preventing major adverse cardiovascular and cerebrovascular events (MACCE) in patients with subclinical coronary atherosclerosis identified on imaging.

Timeline

Start
2023-03-22
Primary completion
2028-12-31
Completion
2031-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg —